Analysts rate Myovant Sciences Ltd. (MYOV:NYE) with a Buy rating and a $16 target

Based on the Myovant Sciences Stock Forecast from 3 analysts, the average analyst MYOV stock price target is USD 16.25 over the next 12 months. Myovant Sciences Ltd’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of MYOV stock forecast is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Myovant Sciences stock price was USD 17.96Myovant Sciences stock price has changed by +1.14% over the past week, +0.56% over the past month and -17.73% over the last year.

Myovant Sciences Ltd stock forecasts from 9 Crowd Analysts, has the average Crowd Analyst target for Myovant Sciences Ltd at USD 18.19 over the next 12 months. Myovant Sciences Ltd’s average Crowd Analyst rating is a Buy.

 

About Myovant Sciences Ltd. (MYOV:NYE):

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

 

What we like:

High market capitalization:

MYOV stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio:

MYOV stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

High volatility:

The total returns for MYOV stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value:

MYOV stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

Myovant Sciences had negative total cash flow in the most recent four quarters.

Negative free cash flow:

Myovant Sciences had negative total free cash flow in the most recent four quarters.

Low Earnings Growth:

MYOV stock has shown below median earnings growth in the previous 5 years compared to its sector.